Learn if You Have a Claim Against Bayer Healthcare

Studies Link Bayer's Trasylol to Stroke and Heart Attack A major independent study indicates that Bayer's antifibrinolytic agent Trasylol doubles the risk of kidney failure and causes other serious adverse events, including stroke and heart attack. Trasylol has been on the market for 13 years, and it reduces the loss of blood during surgery and is typically used during certain heart operations.
Please explain any problems you have had in relation to this case:

Personal Information

First Name

Last Name

Street / Apt /

City, State Zip

Home Phone & Evening Phone (Same) . . & . .

E-Mail Address

Confirm E-Mail

Date Issue/Problem

Terms & Conditions
I acknowledge that I have read and understand and agree to the following legal policies.

Certain features of Lawcash.com require a login - please simply choose a password to continue.

Password

Confirm Password

I'd like to become a Lawcash.com member, receive a free class action ebook, and free class action and recall alerts. Billions of dollars are available each year and I'd like to claim my fair share from bad corporations.

Submit

Other Drugs / Medical Cases of Interest

Washington Light Cigarette Smokers File Actions Against Philip Morris and R.J. Reynolds

Studies have now shown that light cigarette smokers compensate in various ways to make up for reduced levels of nicotine that they get. Two class actions have been filed against R.J. Reynolds Tobacco Company and Philip Morris USA, Inc., respectively, on behalf of all current or former smokers of Marlboro Lights, Camel Lights, Salem Lights, and Winston Lights in the state of Washington. The actions allege that the companies’ marketing strategies violate state consumer protection laws by actively concealing the fact that light cigarette smokers not only get as much or more tar as regular smokers, but may be smoking a more addictive product as well.

Patients Treated in 1996 by “Dr.” David Tremoglie at Bustleton Guidance Center in Philadelphia Receive $3.5 Million Settlement

The parties have reached a tentative $3.5 million settlement in an action filed against David E. Tremoglie, the HMO that employed him, its malpractice insurer, and related companies. The action alleged that Mr. Tremoglie masqueraded as a psychiatrist in violation of state and federal medical licensing regulations. Persons who were treated by Mr. Tremoglie should contact the attorneys for the class as soon as possible, to be able to participate in the settlement.

Class Action Suit Claims Hospital Charged Uninsured More

Uninsured hospital patient Robert Honke filed a lawsuit against Alton Memorial Hospital in Madison County Circuit Court, Illinois. Honke claims AMH charged him more for services than for patients with health insurance. According to the complaint, AMH was to only charge Honke reasonable and customary rates for healthcare services and he would only be obligated to pay reasonable charges for the services he received.

Court Grants Doctors Class-Action Status in Reimbursement Suit

Thousands of Pennsylvania doctors may be eligible to join a lawsuit over a Blue Cross health plan's reimbursement rates after a federal judge granted the plaintiffs class-action status.

American Pharmaceuticals Partners Allegedly Overstated Potential of Breast Cancer Drug Abraxane

A class action has been filed against specialty pharmaceutical company American Pharmaceuticals Partners, Inc. (Nasdaq: APPX) and certain of its officers and directors by stockholders who purchased the company's common stock between February 19, 2002, and September 24, 2003.

Pfizer Accused of Misleading Floridians About Off-Label Uses of Neurontin

A class action has been filed against pharmaceutical manufacturer Pfizer, Inc., Parke-Davis, and Warner-Lambert Company on behalf of persons who paid out-of-pocket expenses for the drug Neurontin (gabapentin), who allege that the companies harmed consumers, by conspiring to circumvent drug approval regulations set up by the U.S. Food and Drug Administration (FDA), and promoting scientifically unproven "off-label" use of the drug, in violation of the federal Racketeer Influenced and Corrupt Organizations Act.